Expression of suppressors of cytokine signaling-3 in Helicobacter pylori-infected rat gastric mucosal RGM-1cells

被引:6
作者
Cha, Boram
Kim, Kyung Hwan
Matsui, Hirofumi
Kim, Hyeyoung [1 ]
机构
[1] Yonsei Univ, Coll Human Ecol, Dept Food & Nutr, Brain Korea Project 21, Seoul 120749, South Korea
[2] Yonsei Univ, Coll Med, Dept Pharmacol, Brain Korea Project Med Sci, Seoul 120752, South Korea
[3] Yonsei Univ, Coll Med, Inst Gastroenterol, Brain Korea Project Med Sci, Seoul 120752, South Korea
[4] Univ Tsukuba, Inst Clin Med, Div Gastroenterol, Tsukuba, Ibaraki 3058575, Japan
来源
SIGNAL TRANSDUCTION PATHWAYS, PT D: INFLAMMATORY SIGNALING PATHWAYS AND NEUROPATHOLOGY | 2007年 / 1096卷
关键词
Helicobacter pylori; RGM-1; cells; SOCS-3;
D O I
10.1196/annals.1397.066
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Our previous studies show that Helicobacter pylori (H. pylori) induces oxidative stress and the expression of proinflammatory cytokines in gastric epithelial cells. H. pylori induces the expression of molecular chaperones and proteins involved in protein-folding machinery as a defense mechanism against cellular stress. The suppressors of cytokine signaling (SOCS) are known as negative regulators of major immune signal pathways. The purpose of this article is to determine whether H. pylori in a Korean isolate (HP99) induces the expression of SOCS in rat gastric mucosal RGM-1 cells as a defense mechanism. As a result, HP99 induced SOCS-3 expression time-dependently in RGM-1 cells. SOCS-1 was not expressed while SOCS-2 expression was not changed by HP99 infection in RGM-1 cells. SOCS-3 might have a defensive role in H. pylori-infected gastric mucosal cells. Further study by manipulating SOCS-3 gene should be performed to investigate the physiological meaning of SOCS-3 induced by H. pylori in gastric mucosal cells.
引用
收藏
页码:24 / 28
页数:5
相关论文
共 13 条
[1]   Oxidative-stress-related proteome changes in Helicobacter pylori-infected human gastric mucosa [J].
Baek, HY ;
Lim, JW ;
Kim, H ;
Kim, JM ;
Kim, JS ;
Jung, HC ;
Kim, KH .
BIOCHEMICAL JOURNAL, 2004, 379 :291-299
[2]   cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors [J].
Censini, S ;
Lange, C ;
Xiang, ZY ;
Crabtree, JE ;
Ghiara, P ;
Borodovsky, M ;
Rappuoli, R ;
Covacci, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (25) :14648-14653
[3]   ASSOCIATION BETWEEN INFECTION WITH HELICOBACTER-PYLORI AND RISK OF GASTRIC-CANCER - EVIDENCE FROM A PROSPECTIVE INVESTIGATION [J].
FORMAN, D ;
NEWELL, DG ;
FULLERTON, F ;
YARNELL, JWG ;
STACEY, AR ;
WALD, N ;
SITAS, F .
BRITISH MEDICAL JOURNAL, 1991, 302 (6788) :1302-1305
[4]   EFFECT OF TREATMENT OF HELICOBACTER-PYLORI INFECTION ON THE LONG-TERM RECURRENCE OF GASTRIC OR DUODENAL-ULCER - A RANDOMIZED, CONTROLLED-STUDY [J].
GRAHAM, DY ;
LEW, GM ;
KLEIN, PD ;
EVANS, DG ;
EVANS, DJ ;
SAEED, ZA ;
MALATY, HM .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (09) :705-708
[5]   Suppressors of cytokine signaling: Relevance to gastrointestinal function and disease [J].
Greenhalgh, CJ ;
Miller, ME ;
Hilton, DJ ;
Lund, PK .
GASTROENTEROLOGY, 2002, 123 (06) :2064-2081
[6]   Inhibition of lipid peroxidation, NF-κB activation and IL-8 production by rebamipide in Helicobacter pylori-stimulated gastric epithelial cells [J].
Kim, H ;
Seo, JY ;
Kim, KH .
DIGESTIVE DISEASES AND SCIENCES, 2000, 45 (03) :621-628
[7]  
Kobayashi I, 1996, IN VITRO CELL DEV-AN, V32, P259
[8]   Controlling cytokine signaling by constitutive inhibitors [J].
Rakesh, K ;
Agrawal, DK .
BIOCHEMICAL PHARMACOLOGY, 2005, 70 (05) :649-657
[9]   Helicobacter pylori in a Korean isolate activates mitogen-activated protein kinases, AP-1, and NF-κB and induces chemokine expression in gastric epithelial AGS cells [J].
Seo, JH ;
Lim, JW ;
Kim, H ;
Kim, KH .
LABORATORY INVESTIGATION, 2004, 84 (01) :49-62
[10]   Transcriptional regulation by thiol compounds in Helicobacter pylori-induced interleukin-8 production in human gastric epithelial cells [J].
Seo, JY ;
Kim, H ;
Kim, KH .
CELL SIGNALING, TRANSCRIPTION, AND TRANSLATION AS THERAPEUTIC TARGETS, 2002, 973 :541-545